Please assess the completion status of the following clinical trial:

Trial Title: Oritavancin Versus IV Vancomycin for the Treatment of Participants With Acute Bacterial Skin and Skin Structure Infection (SOLO I)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants were included in the study if they met all of the following inclusion criteria:~1. Males or females ≥18 years old~2. Diagnosis of ABSSSI suspected or confirmed to be caused by a gram-positive pathogen requiring at least 7 days of IV therapy~3. An ABSSSI included 1 of the following infections: wound infections, cellulitis/erysipelas, major cutaneous abscess~4. ABSSSI must have presented with at least 2 local signs and symptoms and at least 1 sign of systemic inflammation (unless \>70 years of age).~5. Able to give informed consent and willing to comply with all required study procedures~Exclusion Criteria:~Participants were excluded from the study if any of the following exclusion criteria applied prior to randomization:~1. Prior systemic or topical antibacterial therapy with activity against suspected or proven gram-positive pathogens within the preceding 14 days unless:~   * The causative gram-positive pathogen(s) isolated from the ABSSSI site was/were resistant in vitro to the antibacterial(s) that was/were administered with documented clinical progression.~  * Documented failure to previous ABSSSI antibiotic therapy was available. Documentation of treatment failure must have been recorded.~  * Participant received a single dose of a short-acting antibacterial therapy 3 or more days before randomization.~2. Infections associated with, or in close proximity to, a prosthetic device~3. Severe sepsis or refractory shock~4. Known or suspected bacteremia at time of Screening~5. ABSSSI due to or associated with any of the following:~   * Infections suspected or documented to be caused by gram-negative pathogens~  * Wound infections (surgical or traumatic) and abscesses with only gram-negative pathogens~  * Diabetic foot infections~  * Concomitant infection at another site not including a secondary ABSSSI lesion~  * Infected burns~  * A primary infection secondary to a pre-existing skin disease with associated inflammatory changes~  * Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease~  * Any evolving necrotizing process gangrene or infection suspected or proven to be caused by Clostridium species~  * Infections known to be caused by a gram-positive organism with a vancomycin minimum inhibitory concentration \>2 micrograms/milliliter or clinically failing prior therapy with glycopeptides~  * Catheter site infections~6. Allergy or intolerance to aztreonam or metronidazole in a participant with suspected or proven polymicrobial wound infection involving gram-negative and/or anaerobic bacteria~7. Was currently receiving chronic systemic immunosuppressive therapy~8. Acquired immunodeficiency syndrome with cluster of differentiation 4 count \<200 cells/cubic millimeter~9. Neutropenia~10. Significant or life-threatening condition that would confound or interfere with the assessment of the ABSSSI~11. Women who were pregnant or nursing~12. History of immune-related hypersensitivity reaction to glycopeptides~13. Participants that required anticoagulant monitoring with an activated partial thromboplastin time~14. Contraindication to vancomycin~15. Participants unwilling to forego blood and/or blood product donation~16. Treatment with investigational medicinal product within 30 days before enrollment and for the duration of the study~17. Investigational device present, or removed \<30 days before enrollment, or presence of device-related infection~18. Participants unlikely to adhere to the protocol, comply with study drug administration, or complete the clinical study~19. Severe hepatic disease~20. Presence of hyperuricemia~21. Unwilling to refrain from chronic use of any medication with antipyretic properties

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single-Dose IV Oritavancin Diphosphate (Type: EXPERIMENTAL): None
- IV Vancomycin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete